Skip to main content
Retour
GNGBF logo

Getinge AB (publ)

Qualité des données : 100%
Survendu
GNGBF
OTC Healthcare Medical - Devices
23,23 €
▼ 1,52 € (-6,14%)
Cap. Boursière : 5,90B
Également cotée sous GNGBY OTC
Fourchette du Jour
23,23 € 23,23 €
Fourchette 52 Semaines
18,82 € 24,75 €
Volume
200
Moyenne 50J / 200J
22,92 € / 21,43 €
Clôture Précédente
23,23 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 2,6 0,3
P/B 0,2 3,0
ROE % 7,2 3,7
Net Margin % 6,5 3,8
Rev Growth 5Y % 6,6 10,0
D/E 0,4 0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2029 16,84 €
16,02 € – 18,45 €
 43,08B 1
FY2028 14,76 €
14,05 € – 16,18 €
 38,38B 1
FY2027 13,31 €
12,67 € – 14,59 €
 36,62B 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-01-27 4,07 € 0,34 € -91,5%
2025-10-21 0,23 € 0,22 € -3,0%
2025-07-18 0,19 € 0,20 € +4,2%
2025-04-21 0,20 € 0,11 € -45,6%
2025-01-28 0,32 € 0,22 € -32,2%
2024-10-18 0,24 € 0,00 € -99,7%
2024-07-18 0,16 € 0,18 € +9,1%
2024-04-22 0,14 € 0,16 € +10,6%

Dividend History

Yield

0,02%

Payout Ratio

N/A

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Revenue grew 6,63% annually over 5 years — modest growth
Earnings grew 37,85% over the past year
Debt/Equity of 0,37 — conservative balance sheet
Generating 2,64B in free cash flow
P/E of 2,61 — trading at a low valuation
PEG of 0,65 suggests growth is underpriced

Croissance

Revenue Growth (5Y)
6,63%
Revenue (1Y)0,60%
Earnings (1Y)37,85%
FCF Growth (3Y)28,17%

Qualité

Return on Equity
7,23%
ROIC7,79%
Net Margin6,46%
Op. Margin11,97%

Sécurité

Debt / Equity
0,37
Current Ratio1,32
Interest Coverage6,52

Valorisation

P/E Ratio
2,61
Forward P/EN/A
P/B Ratio0,20
EV/EBITDA3,20
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0,60% Revenue Growth (3Y) 4,82%
Earnings Growth (1Y) 37,85% Earnings Growth (3Y) -3,25%
Revenue Growth (5Y) 6,63% Earnings Growth (5Y) -6,62%
Profitability
Revenue (TTM) 34,97B Net Income (TTM) 2,26B
ROE 7,23% ROA 4,00%
Gross Margin 44,34% Operating Margin 11,97%
Net Margin 6,46% Free Cash Flow (TTM) 2,64B
ROIC 7,79% FCF Growth (3Y) 28,17%
Safety
Debt / Equity 0,37 Current Ratio 1,32
Interest Coverage 6,52
Dividends
Dividend Yield 0,02% Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 2,61 Forward P/E N/A
P/B Ratio 0,20 P/S Ratio 0,17
PEG Ratio 0,65 Forward PEG N/A
EV/EBITDA 3,20 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 44,63%
Market Cap 5,90B Enterprise Value 13,39B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 34,97B 34,76B 31,83B 28,29B 27,05B
Net Income 2,26B 1,64B 2,41B 2,49B 2,97B
EPS (Diluted) 8,29 6,01 8,86 9,15 10,90
Gross Profit 15,51B 16,15B 14,50B 13,41B 13,58B
Operating Income 4,19B 2,85B 3,74B 3,63B 4,37B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 56,51B 63,92B 53,59B 52,03B 44,56B
Total Liabilities 27,01B 30,71B 23,18B 21,58B 19,38B
Shareholders' Equity 29,43B 33,01B 30,17B 30,04B 24,75B
Total Debt 10,88B 10,73B 8,08B 5,82B 4,31B
Cash & Equivalents 3,40B 2,96B 2,73B 5,68B 4,08B
Current Assets 17,23B 18,16B 16,65B 19,11B 15,07B
Current Liabilities 13,04B 15,05B 13,19B 11,99B 10,61B

Scores de Stratégies

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#321 of 827
48
Value Defensive Investing (Benjamin Graham)
#148 of 709
48

Activité Récente

Entré Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré Defensive Investing (Benjamin Graham)
Mar 24, 2026